Mental health nursing expert Jill Archibald provided evidence to the Lampard Inquiry that Oxevision cameras can increase patient paranoia and cause some patients to scream at the device.

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

Valdo Calocane was diagnosed with paranoid schizophrenia in 2020, had been sectioned four times under the Mental Health Act, and pleaded guilty to manslaughter on the grounds of diminished responsibility in January 2024

A study of U.S. health data published in Lancet Psychiatry reported that GLP-1 users with schizophrenia and type 2 diabetes were less likely to be admitted to a psychiatric hospital than patients taking other types of diabetes medication

A study of U.S. health records published in Lancet Psychiatry found that patients with both schizophrenia and type 2 diabetes who were prescribed GLP-1 receptor agonists had a 24% lower risk of psychiatric hospital admission than those not taking GLP-1s

Patients with schizophrenia and type 2 diabetes prescribed GLP-1 receptor agonists were 29% less likely to visit an emergency department for a mental health crisis compared to those not taking GLP-1s, according to a Lancet Psychiatry study

The authors of the Lancet Psychiatry study published in October 2026 emphasized that randomized controlled trials are required to confirm whether GLP-1 receptor agonists directly reduce psychiatric acute care needs in patients with schizophrenia

Study authors advised that GLP-1 receptor agonists should not be considered a primary psychiatric treatment or prescribed solely to reduce psychiatric hospital admissions based on current evidence

Research published in Lancet Psychiatry found schizophrenia patients taking GLP-1 diabetes drugs had a 29% lower likelihood of emergency room visits for mental health crises compared to non-users.

A study in Lancet Psychiatry using U.S. health records showed people with schizophrenia taking GLP-1 drugs for diabetes were 24% less likely to be admitted to psychiatric hospitals.

Cannabis consumption poses a severe public health risk through induced psychosis

A NHS report into mental health services following Suzanne Brown's killing identified eight failures, including a lack of risk assessments or professional monitoring after Jake Neate's clozapine was stopped.

A July 2026 letter from Jake Neate's doctor at Rampton hospital described his mental health disorder as very resistant to treatment despite overall progress and recent episodes of decline.

A Monash University study found psychotic disorders accounted for 40% of cannabis-related hospital admissions in Victoria between 2013 and 2023, making psychosis the most common primary diagnosis.

Jake Neate, a 45-year-old diagnosed with paranoid schizophrenia, has been held at Rampton high-security hospital for eight years under an indefinite section 37 order requiring Home Office permission for release.

Jan Neate stated that her son Jake Neate experiences periods of seclusion, self-harm, and seizures while incarcerated at Rampton hospital, during which family members receive minimal information from staff.

In December 2017, Jake Neate stabbed his partner Suzanne Brown 173 times after experiencing severe psychosis following the abrupt cessation of his schizophrenia medication clozapine.

The FDA granted 510(k) clearance to Motivista, a prescription digital therapeutic developed by Click Therapeutics, as an adjunctive treatment for adults with negative symptoms of schizophrenia.

Motivista delivers cognitive behavioral therapy techniques, including cognitive restructuring, behavioral activation, social skills training, and positive affect training, via lessons and daily check-ins.

Click Therapeutics warned that Motivista is not for acute symptoms, active suicide risk, patients under age 18, or those not taking antipsychotics.

State Medicaid programs should grant protected class status to Motivista